Overview
- Researchers compared 39,392 men in Germany's PROBASE PSA‑plus‑MRI trial with just over 2.8 million women in the national mammography program.
- The screening pathways found similar shares of invasive or spreading cancers—about 60–74% for prostate versus roughly 73% for breast.
- PSA testing with MRI generated higher false‑positive results than mammography at about 37–42% versus around 10%.
- Biopsies prompted by the prostate pathway were far more likely to confirm significant cancer—about 50–68% versus 10% in breast screening—while overall biopsy referral rates were similar due to risk stratification.
- Prostate screening detected more non‑aggressive tumors (26–31% vs 22%), prompting caution from charities and clinicians about overtreatment as UK officials review whether to expand screening.